

Special Issue

Nanoparticles for Glioblastoma Therapy

Message from the Guest Editors

Glioblastoma (GBM) remains a formidable challenge with limited therapeutic options and poor prognosis. Nanoparticle-based drug delivery systems offer a promising avenue to overcome obstacles in GBM treatment, including the blood–brain barrier (BBB) and tumor heterogeneity.

This Special Issue highlights the potential of nanoparticles for enhancing GBM therapy. We encourage submissions presenting preclinical studies that demonstrate the ability of nanoparticles to enhance GBM treatment efficacy by increasing drug concentration at the tumor site, reducing systemic toxicity, and overcoming drug resistance mechanisms. Submissions focusing on functionalized nanoparticles with specific ligands or antibodies for active GBM cell targeting are also highly encouraged. This Special Issue aims to gather cutting-edge research that will advance the translation of these promising findings into clinical applications and ultimately improve the survival and quality of life of individuals with GBM.

Guest Editors

Dr. Shambhavi Pandey

School of Bioengineering, IQS, Ramon Llull University, 08017 Barcelona, Spain

Dr. Benjamí Oller-Salvia

School of Bioengineering, IQS, Ramon Llull University, Barcelona, 08017

Deadline for manuscript submissions

20 January 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/242219

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).